Chemours (CC)
(Delayed Data from NYSE)
$19.79 USD
-0.66 (-3.23%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $19.80 +0.01 (0.05%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$19.79 USD
-0.66 (-3.23%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $19.80 +0.01 (0.05%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth C Momentum F VGM
Zacks News
Here's Why Chemours (CC) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Chemours (CC) have what it takes to be a top stock pick for momentum investors? Let's find out.
Book Profits by Investing in These High Earnings Yield Picks
by Rimmi Singhi
Invest in high earnings yield stocks like PBR, HIMX, TEN and CC for sturdy gains.
Should Value Investors Buy Chemours (CC) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Chemours (CC) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
Chemours' (CC) Q1 results benefit from higher sales in Titanium Technologies and Advanced Performance Materials units driven by demand recovery.
Chemours (CC) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Chemours (CC) delivered earnings and revenue surprises of 4.41% and 3.80%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Central Banks Start to Care About Fundamentals?
by John Blank
Macro-data has been much stronger than expected.¿¿¿¿¿¿ Still, the only thing that matters is NOT whether stock traders (or pundits) take note of strong data. It is whether the Fed and other major central banks care.
Chemours (CC) Starts Strategic Review of Mining Solutions Unit
by Zacks Equity Research
Chemours' (CC) overall goal is to position each of its businesses, including Mining Solutions, to deliver the highest level of profitable growth.
3 Reasons Why Growth Investors Shouldn't Overlook Chemours (CC)
by Zacks Equity Research
Chemours (CC) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Chemours (CC) Tops Earnings and Revenue Estimates in Q4
by Zacks Equity Research
Chemours' (CC) fourth-quarter performance benefits from a global macroeconomic recovery.
Is Chemours (CC) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Chemours (CC) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Chemours' (CC) fourth-quarter 2020 results are likely to reflect recovery in demand across all markets and regions as well as benefits from cost-cutting measures.
Is The Chemours (CC) Stock Outpacing Its Basic Materials Peers This Year?
by Zacks Equity Research
Is (CC) Outperforming Other Basic Materials Stocks This Year?
New Strong Buy Stocks for January 28th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Chemours (CC) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Chemours (CC) closed the most recent trading day at $27.28, moving +1.83% from the previous trading session.
Should Value Investors Buy Chemours (CC) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
New Strong Buy Stocks for January 25th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Is The Chemours (CC) Outperforming Other Basic Materials Stocks This Year?
by Zacks Equity Research
Is (CC) Outperforming Other Basic Materials Stocks This Year?
The Zacks Analyst Blog Highlights: Altus Midstream, Chemours, D.R. Horton, DocuSign and Harley-Davidson
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Altus Midstream, Chemours, D.R. Horton, DocuSign and Harley-Davidson
New Strong Buy Stocks for January 14th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today.
Wall Street Unfazed by Lingering Unease in Washington: 5 Picks
by Tirthankar Chakraborty
Expectations about stimulus package, Fed's supportive stance, and vaccine rollout have helped investors remain optimistic, which calls for investing in growth stocks like D.R. Horton (DHI) and DocuSign (DOCU).
3 Reasons Why Chemours (CC) Is a Great Growth Stock
by Zacks Equity Research
Chemours (CC) possesses solid growth attributes, which could help it handily outperform the market.
Are You Looking for a Top Momentum Pick? Why Chemours (CC) is a Great Choice
by Zacks Equity Research
Does Chemours (CC) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Chemours (CC) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
6 Stocks Trading Near 52-Week Highs That Can Appreciate Further
by Anirudha Bhagat
Investors target stocks that have been on a bullish run, lately. Stocks seeing price strength have higher chances of carrying the momentum ahead.
Chemours (CC) Stock Rallies 79% in 6 Months: What's Driving It?
by Zacks Equity Research
Chemours (CC) gains on a recovery in demand from the coronavirus-induced slowdown, strong execution and its cost-reduction measures.